Xiaojia Wang

机构：Zhejiang Cancer Hospital, Ningxia Medical University, Ningxia Medical University General Hospital · ORCID：0000-0002-7005-0842

发表论文 286 篇 · 总被引 8867 次 · h-index 35

代表论文

• Sacituzumab tirumotecan in previously treated metastatic triple-negative breast cancer: a randomized phase 3 trial (2025 · Nature Medicine · 被引 53)
• Trastuzumab deruxtecan in HER2-low metastatic breast cancer: long-term survival analysis of the randomized, phase 3 DESTINY-Breast04 trial (2025 · Nature Medicine · 被引 30)
• Capivasertib plus fulvestrant in patients with HR-positive/HER2-negative advanced breast cancer: phase 3 CAPItello-291 study extended Chinese cohort (2025 · Nature Communications · 被引 15)
• An aptamer-drug conjugate for promising cancer therapy with comprehensive evaluation from rodents to non-human primates (2025 · Signal Transduction and Targeted Therapy · 被引 12)
• Sacituzumab tirumotecan (sac-TMT) as first-line treatment for unresectable locally advanced/metastatic triple-negative breast cancer (a/mTNBC): Initial results from the phase II OptiTROP-Breast05 study. (2025 · Journal of Clinical Oncology · 被引 11)
• Lerociclib plus fulvestrant in patients with HR+/HER2− locally advanced or metastatic breast cancer who have progressed on prior endocrine therapy: LEONARDA-1 a phase III randomized trial (2025 · Nature Communications · 被引 11)